全球基因和細胞治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球基因和細胞治療市場預計將從2025年的399.3億美元成長至2034年的1,890.7億美元，2026年至2034年的複合年成長率（CAGR）為18.86%。隨著生物技術和製藥公司開發和推進旨在透過改造遺傳物質或利用活細胞治療嚴重的療法，該市場正在不斷擴張。基因療法涉及引入、替換或改造遺傳物質，而細胞療法則利用基因改造或其他方式改變的細胞來產生治療效果。基因工程、病毒載體、細胞製造和遞送技術的進步正在推動臨床開發。對罕見疾病、腫瘤和其他疾病的投入增加，正在為該領域創造更廣泛的開發平臺。

研究在許多領域取得了進展，包括病毒和非病毒遞送系統、基因編輯、基因修飾免疫細胞以及在再生醫學中的應用。基於 CRISPR 的基因編輯等技術正在拓展標靶基因修飾的可能性，而基於細胞的方法也正在癌症和其他疾病的治療中被探索。製造流程的創新同樣至關重要，因為這些療法通常需要複雜的流程，涉及專用設施、品管和個人化生產。自動化、分析和封閉式系統處理技術的進步正在幫助研發人員應對其中一些製造方面的挑戰。

未來前景取決於臨床結果、監管進展、生產規模化以及患者的長期追蹤。如果能夠成功解決安全性和有效性方面的挑戰，基因編輯和細胞工程技術的進步有望擴大可治療疾病的範圍。生產效率的提升也將增加治療的​​可近性，並提升商業性可行性。在科學合理的範圍內，研發人員正擴大探索標準化和現成的解決方案。隨著治療產品線的成熟，生物技術公司、製藥企業、醫院和專業服務供應商之間的夥伴關係預計仍將在市場發展中發揮至關重要的作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業趨勢。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供以資料為基礎的市場規模和成長模式展望，預測期為指定期間。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以預測未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區特定分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球基因與細胞治療市場：依治療類型分類

• 市場分析、洞察與預測
• 細胞療法（幹細胞、T細胞、樹突細胞、NK細胞）
• 基因治療（生殖細胞株基因治療、體細胞基因治療）

第5章 全球基因與細胞治療市場：依應用分類

• 市場分析、洞察與預測
• 皮膚科
• 肌肉骨骼系統
• 腫瘤學
• 免疫學
• 循環系統和神經科學
• 其他（泌尿器官系統疾病、感染疾病、眼科疾病、視網膜疾病等）

第6章 全球基因與細胞治療市場：依最終使用者分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 其他（研究機構、學術機構等）

第7章 全球基因與細胞治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis International AG
  • Pfizer Inc
  • Sanofi SA
  • Amgen Inc
  • Regeneron Pharmaceuticals Inc
  • Biogen Inc
  • UniQure NV
  • JCR Pharmaceuticals Co. Ltd
  • Gene Biotherapeutics
  • Kolon TissueGene Inc
  • Horama SA
  • MeiraGTx Limited
  • Gilead Sciences Inc
  • Organogenesis Inc

The global gene and cell therapy market size is expected to reach USD 189.07 Billion in 2034 from USD 39.93 Billion in 2025, growing at a CAGR of 18.86% during 2026-2034.This market is expanding as biotechnology and pharmaceutical companies advance therapies designed to modify genetic material or use living cells to treat serious diseases. Gene therapies can introduce, replace, or modify genetic material, while cell therapies use engineered or otherwise modified cells to produce therapeutic effects. Advances in genetic engineering, viral vectors, cell manufacturing, and delivery technologies are supporting clinical development. Increasing investment in rare diseases, oncology, and other conditions is creating a broader development pipeline across the sector.

Research is progressing across viral and non-viral delivery systems, gene editing, engineered immune cells, and regenerative applications. Technologies such as CRISPR-based editing are expanding the possibilities for targeted genetic modification, while cell-based approaches are being investigated across cancers and other diseases. Manufacturing innovation is equally important because these therapies often require complex processes involving specialized facilities, quality controls, and individualized production. Improvements in automation, analytics, and closed-system processing are helping developers address some of these manufacturing challenges.

Future prospects will depend on clinical outcomes, regulatory progress, manufacturing scalability, and long-term patient follow-up. Advances in gene editing and cell engineering may expand the number of treatable conditions if safety and efficacy challenges are successfully addressed. More efficient manufacturing could also improve access and commercial viability. Developers are increasingly exploring standardized or off-the-shelf approaches where scientifically appropriate. As the therapeutic pipeline matures, partnerships among biotechnology companies, pharmaceutical manufacturers, hospitals, and specialized service providers are expected to remain important to market development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• Cell Therapy (Stem Cells, T Cells, Dendritic Cells, NK Cells)
• Gene Therapy (Germline Gene Therapy, Somatic Gene Therapy)

By Application

• Dermatology
• Musculoskeletal
• Oncology
• Immunology
• Cardiology & Neurology
• Others (Urinary Problems, Infectious Disease, Ophthalmic Diseases, Retinal Diseases, And Others)

By End User

• Hospitals
• Clinics
• Others (Research Institutes, Academic Institutes, etc.)

COMPANIES PROFILED

• Novartis International AG, Pfizer Inc., Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences Inc., Organogenesis Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENE AND CELL THERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Cell Therapy (Stem Cells, T Cells, Dendritic Cells, NK Cells) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Therapy (Germline Gene Therapy, Somatic Gene Therapy) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENE AND CELL THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Cardiology & Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others (Urinary Problems, Infectious Disease, Ophthalmic Diseases, Retinal Diseases, And Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENE AND CELL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others (Research Institutes, Academic Institutes, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENE AND CELL THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENE AND CELL THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis International AG
  • 9.2.2 Pfizer Inc
  • 9.2.3 Sanofi S.A
  • 9.2.4 Amgen Inc
  • 9.2.5 Regeneron Pharmaceuticals Inc
  • 9.2.6 Biogen Inc
  • 9.2.7 UniQure N.V
  • 9.2.8 JCR Pharmaceuticals Co. Ltd
  • 9.2.9 Gene Biotherapeutics
  • 9.2.10 Kolon TissueGene Inc
  • 9.2.11 Horama S.A
  • 9.2.12 MeiraGTx Limited
  • 9.2.13 Gilead Sciences Inc
  • 9.2.14 Organogenesis Inc